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Kidney ischemia-reperfusion (I/R) injury is a common cause of acute kidney
injury. We tested whether dexmedetomidine (Dex), an alpha2 adrenoceptor
(a2-AR) agonist, protects against kidney I/R injury. Sprague–Dawley rats were
divided into four groups: (1) Sham-operated group; (2) I/R group (40 min
ischemia followed by 24 h reperfusion); (3) I/R group + Dex (1 lg/kg i.v.
60 min before the surgery), (4) I/R group + Dex (10 lg/kg). The effects of Dex
postconditiong (Dex 1 or 10 lg/kg i.v. after reperfusion) as well as the effects
of peripheral a2-AR agonism with fadolmidine were also examined. Hemody-
namic effects were monitored, renal function measured, and acute tubular dam-
age along with monocyte/macrophage infiltration scored. Kidney protein kinase
B, toll like receptor 4, light chain 3B, p38 mitogen-activated protein kinase
(p38 MAPK), sirtuin 1, adenosine monophosphate kinase (AMPK), and endo-
thelial nitric oxide synthase (eNOS) expressions were measured, and kidney
transciptome profiles analyzed. Dex preconditioning, but not postconditioning,
attenuated I/R injury-induced renal dysfunction, acute tubular necrosis and
inflammatory response. Neither pre- nor postconditioning with fadolmidine
protected kidneys. Dex decreased blood pressure more than fadolmidine, ame-
liorated I/R-induced impairment of autophagy and increased renal p38 and
eNOS expressions. Dex downregulated 245 and upregulated 61 genes represent-
ing 17 enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways,
in particular, integrin pathway and CD44. Ingenuity analysis revealed inhibition
of Rac and nuclear factor (erythroid-derived 2)-like 2 pathways, whereas aryl
hydrocarbon receptor (AHR) pathway was activated. Dex preconditioning ame-
liorates kidney I/R injury and inflammatory response, at least in part, through
p38-CD44-pathway and possibly also through ischemic preconditioning.
Abbreviation
AHR, aryl hydrocarbon receptor; AMPK, adenosine monophosphate kinase; ANO-
VA, analysis of variance; ATN, acute tubular necrosis; BP, blood pressure; Dex,
dexmedetomidine; eNOS, endothelial nitric oxide synthase; HR, heart rate; I/R,
ischemia-reperfusion; IGF-1, insulin-like growth factor 1; IPC, ischemic precondi-
tioning; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen acti-
vated protein kinases; MAP, mean arterial blood pressure; Nec-1, necrostatin-1; PK,
pharmacokinetic; RAS, renin–angiotensin system; RIPK1, receptor-interacting pro-
tein kinase 1; SD, Sprague–Dawley; SNS, sympathetic nervous system; TNF, tumor
necrosis factor; a1-AR, alpha1 adrenoceptors; a2-AR, alpha2 adrenoceptor.
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and
no modifications or adaptations are made.
2014 | Vol. 2 | Iss. 3 | e00045
Page 1
Introduction
Kidney ischemia-reperfusion (I/R) injury is a common
cause of acute kidney injury which often occurs in the
context of trauma, sepsis, and multiorgan failure. Despite
advances in preventive strategies and support measures,
acute kidney injury is associated with high morbidity and
mortality. Causes that present I/R – injury are numerous.
It is known that hypotension, hypoperfusion, hypoxia,
oxidative stress, and renal vasoconstriction contribute to
its pathogenesis. (Kunzendorf et al. 2010) This leads to
tubular and endothelial cell injury, mitochondrial dam-
age, and further renal vasoconstriction due to activation
of the sympathetic nervous system (SNS) and renin–
angiotensin–aldosterone axis (Noiri et al. 2001; Devarajan
2006; Hasegawa et al. 2010). There is no specific medica-
tion for I/R-induced acute kidney injury (AKI) in clinical
use.
The alpha2 adrenoceptor (a2-AR) agonist dexmedetomi-
dine (Dex) has sedative, analgesic, and sympatolytic prop-
erties (Mantz et al. 2011). There is accumulating evidence
to suggest that Dex protects tissues, including kidneys,
against ischemic injuries in animal models by affecting vari-
ous intracellular kinases, oxidant status, and adhesion mol-
ecules (Maier et al. 1993; Kuhmonen et al. 1997; Jolkkonen
et al. 1999; Gu et al. 2011b; Ibacache et al. 2012; Kilic et al.
2012; Tufek et al. 2013). Dex is already in clinical use as a
sedative for intensive care unit patients who require only
mild sedation and it seems to enhance renal function also
in some clinical cases (Kulka et al. 1996; Frumento et al.
2006). The mechanism(s) behind the possible renoprotec-
tive action remains still elusive, especially as Dex has been
shown to exert some a2-receptor-independent effects (Gu
et al. 2011b). The hypotensive effect of Dex might be an
asset or a limitation depending on the clinical setting
(Coursin et al. 2001; Richa et al. 2004).
We have recently shown in a murine model of renal I/
R, that caloric restriction, and thus metabolic precondi-
tioning, attenuates acute kidney injury through peroxi-
some proliferator-activated receptor gamma coactivator
1a-eNOS pathway and enhanced autophagy (Lempi€ainen
et al. 2013). Furthermore, we also demonstrated that
metabolic preconditioning with 5-aminoimidazole-4-
carboxamide-1-b-D-ribofuranoside, an adenosine mono-
phosphate kinase (AMPK) activator, also ameliorated I/R-
induced kidney injury (Lempi€ainen et al. 2012).
The aim of the present study was to further explore the
mechanisms behind the renoprotective effects of Dex. In
particular, we investigated whether the time-course of
drug administration (preconditioning vs. postcondition-
ing) impacts on the therapeutic effect of Dex, and
whether metabolic reprograming is involved. Further-
more, we compared the therapeutic effects of Dex with
those of peripherally acting a2-AR agonist fadolmidine
(Fado) in our renal I/R injury model.
Materials and Methods
Experimental animals, renal ischemia/
reperfusion, drug treatments and sample
preparation
All procedures were approved by the Provincial State Office
of Southern Finland (approval number STH059A). Every
effort was made to ensure than animals experienced mini-
mal discomfort. We used 6–7-week-old male Sprague–
Dawley (SD) rats for this study, and results are recorded in
accordance with the Animal Research: Reporting In Vivo
Experiments guidelines for reporting experiments involving
animals. Rats were kept under 12-h light/12-h dark cycle
and they had free access to food and water.
An established murine model of acute kidney I/R injury
was used (Forbes et al. 2000). Experimental protocols and
sample preparation are described elsewhere (Lempi€ainen
et al. 2012). Briefly, rats were anesthetized with isoflurane,
intubated, abdominal incisions were made, and bilateral
renal ischemia was induced by clamping renal pedicles for
40 min with microvascular clamps. Control animals were
subjected to sham operation without renal pedicle clamp-
ing. The rats were hydrated with warm saline during the
operation and the body temperature was maintained con-
stantly at 37°C by using a heating pad until awake. The
wounds were sutured after removing the clips, and the
animals were allowed to recover. Buprenorphine (0.1 mg/
kg s.c.) was used as postoperative analgesia.
Protocol 1: Effects of Dex preconditioning
on kidney I/R injury
Six to seven-week-old SD rats were divided into four
groups (n = 8–11 per group): (1) Sham-operated group;
(2) I/R group (40 min bilateral ischemia followed by 24 h
of reperfusion; (3) I/R group + Dex (1 lg/kg i.v. given
60 min before the surgery), (4) I/R group + Dex (10 lg/kg
i.v.). Dex was given as an intravenous bolus 60 min before
the surgery. In additional experiments, the effects of Dex
infusions (0.1 or 0.3 lg/kg/min started 60 min before sur-
gery and continued until 30 min reperfusion period)
(n = 10 in both groups) on kidney I/R injury were also
examined. Blood samples were taken during the follow-up
period for pharmacokinetic (PK) analyses. To further inves-
tigate the molecular mechanisms of Dex, we conducted an
additional study with the following four groups (n = 10 in
each group): (1) I/R group, (2) I/R group + Dex (10 lg/kg
i.v), (3) I/R group + necroptosis inhibitor necrostatin-1
(Nec-1) (1.65 mg/kg i.p. given 15 min before operation),
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(4) I/R group + Dex + Nec-1. The drug dosage of Nec-1
was selected from previous in vivo studies performed in
mice (Linkermann et al. 2012, 2013).
Protocol 2: Effects of Dex postconditioning
on kidney I/R injury
Six to seven-week-old SD rats were divided into four
groups (n = 5–10 per group): (1) Sham-operated group;
(2) I/R group (40 min bilateral ischemia followed by 24 h
of reperfusion; (3) I/R group + Dex (1 lg/kg i.v. given
immediately after the 40 min ischemic period), (4) I/R
group + Dex (10 lg/kg i.v.).
Protocol 3: Effects of fadolmidine
pre- and postconditioning on kidney I/R injury
In these studies, the effects pre- and postconditioning with a
peripheral a2-AR agonist fadolmidine, on kidney I/R injury
were examined as outlined in protocols 1 and 2. Fadolmidine
preconditioning was given as an intravenous bolus 60 min
before the surgery at the dosage of 1 or 10 lg/kg (n = 7–18
per group). Fadolmidine postconditioning (n = 5–10 per
group) was given as an intravenous bolus (1 and 10 lg/kg)
given immediately after the 40 min ischemic period.
Protocol 4: Effects of Dex and fadolmidine
preconditioning and infusions
on hemodynamics in kidney I/R injury
In a separate experiment (n = 5–6 per group), the hemo-
dynamic effects of Dex and fadolmidine, 1 lg/kg and
10 lg/kg preconditioning bolus groups, and 0.1 lg/kg/
min and 0.3 lg/kg/min infusion groups, were continu-
ously recorded by using intra-arterial catheter inserted
into carotid artery and a Powerlab system (AD Instru-
ments, Germany). Twenty four hours after the operation,
the rats were anesthetized with isoflurane and blood sam-
ples were collected from inferior vena cava with 5 mL
syringe and 22G needle for biochemical measurements.
The kidneys were excised, washed with ice-cold saline,
blotted dry, and weighed. Tissue samples for histology
were fixated in 10% formalin and processed to paraffin
with routine methodology. Samples for immunohisto-
chemistry were snap-frozen in 38°C isopentane. For
protein and gene expression studies, kidney samples were
snap-frozen in liquid nitrogen and stored at 80°C until
assayed. All samples were stored at 80°C until assayed.
Kidney histology
For histological examination, 4-lm thick paraffin sec-
tions were cut and stained with hematoxylin–eosin.
Morphological changes from the whole cross-sectional
area of cortex and medulla were assessed (n = 5–11) by
pathologist (P. F.) according to acute tubular necrosis
(ATN) – scoring system (magnification 2009, ≥20 fields
per kidney section quantified using the ATN scoring
system) as described elsewhere (Lempi€ainen et al. 2012).
Evaluation of histopathological changes included the
loss of tubular brush border, tubular dilatation, cast
formation, and cell lysis. Tissue damage was quantified
in a blinded manner and scored according to the per-
centage of damaged tubules in the sample: 0, no dam-
age; 1, <25% damage; 2, 25–50% damage; 3, 50–75%
damage; and 4, >75% damage.
Immunohistochemistry
For immunohistochemistry, frozen kidneys were pro-
cessed and semiquantitative scoring of inflammatory
cells was performed (n = 10 per group) as described
elsewhere (Lempi€ainen et al. 2012). The relative amount
of antibody-positive signal in cortical and medullary
areas per sample was determined with computerized
densitometry (Leica IM500 and Leica QWIN software;
Leica Microsystems AG, Heerbrugg, Switzerland). Pri-
mary monoclonal antibody against rat monocyte/macro-
phage ED-1 (1/300; Serotec Ltd, Oslo, Norway) as well
as peroxidase-conjugated rabbit anti-mouse and biotiny-
lated anti-rabbit (Vector Laboratories Inc., Burlingame,
CA) secondary antibodies (Dako A/S, Glostrup,
Denmark) were used.
Western blotting
Western blotting of the target proteins (n = 5–11 per
group) was performed as described elsewhere
(Lempi€ainen et al. 2013). Sirtuin 1 (SIRT1) expression
was assessed from nuclear proteins. The following anti-
bodies were used: protein kinase B (Akt) (Akt, 1/1000;
Cell Signaling, Beverly, MA), pAkt (Phospho-Akt, 1/750;
Cell Signaling), AMPK (AMPKalpha, 1/750; Cell Signal-
ing), pAMPK (pAMPKalpha, 1/1000; Cell Signaling),
endothelial nitric oxide synthase (eNOS) (NOS3, 1/500;
Santa Cruz Biotechnologies, Santa Cruz, CA), eNOS-P
(p- NOS3, 1/500; Santa Cruz Biotechnologies), light
chain 3B (LC-3B) (LC3B, 1/500; Cell Signaling), p38
(p38 MAP Kinase, 1/1000; Cell Signaling), phospho-p38
(Phospho-p38 MAPK, 1/1000; Cell Signaling), toll like
receptor 4 (TLR4) (Anti-TLR4, 1/1000; Abcam,
Cambridge, MA) ,and SIRT1 (Anti-Sir2, 1/1000;
Upstate, Millipore, Temecula, CA). Tubulin (Antialpha
tubulin, 1/3000; Abcam) and beta-actin (beta-Actin,
1/3000; Cell Signaling) were used as the loading
controls.
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Microarray
Kidney samples from I/R injury group with and with-
out Dex preconditioning (n = 3 in both groups) were
powdered in liquid nitrogen. Total RNA was isolated
with TRIzol Reagent (Invitrogen, Carlsbad, CA) and
purified with the RNeasy mini kit (Qiagen, Valencia,
CA) according to the manufacturers’ instructions. The
concentration and integrity of total RNA were analyzed
with a spectrophotometer and 2100 Bionanalyzer
(Agilent Technologies, Santa Clara, CA). Further, sam-
ple processing and hybridization to Sureprint G3 Rat
GE 8x60K microarrays (Agilent Technologies) represent-
ing over 30,000 rat transcripts was performed by Biom-
edicum Functional Genomics Unit (www.helsinki.fi/
fugu/). Data were normalized to the median with the
RMA reprocessing algorithm and analyzed with Gene-
spring 11 software (Agilent Technologies). Differentially
expressed probe sets were selected based on filtering by
the parametric statistical analysis not assuming equal
variances (Welch-type t-test) with P < 0.05 as a thresh-
old for significance, followed by filtering for fold
change (1.2-fold) between the compared groups. The
functional annotation describing the categorical data for
gene ontology and pathway information for the lists of
genes were performed with DAVID (Database for Anno-
tation, Visualization and Integrated Discovery, 2008)
(Dennis et al. 2003). Data were also analyzed through
the use of IPA (Ingenuity Systems, www.ingenuity.
com).
Biochemical determinations
Serum creatinine, electrolytes, lipids, and liver enzymes
were measured by routine laboratory techniques (ADVIA
1650 Chemistry System; Siemens Healthcare Diagnostics
Inc., Deerfield, IL).
Measurement of plasma Dex concentration
In the PK study, blood samples were taken at 0.25, 0.5, 2,
and 3 h from the tail vein of conscious rats. Dex concen-
trations were determined by a validated liquid
chromatography–mass spectrometry/mass spectrometry
method. The estimate for plasma concentration at 1 h
was performed using nonlinear fit in GraphPad Prism
software (v6.02, San Diego, CA).
Drug concentrations after different Dex infusion rates
were measured from plasma samples taken just before the
reperfusion phase (100 min after beginning of infusion)
(n = 7 in each infusion group and n = 2–3 for each time
point after i.v. bolus). For bolus and infusion PK studies,
the lower limits of quantification were 0.0200 and
0.100 ng/mL for Dex.
Statistical analysis
Data are presented as the mean + SEM. Statistically signifi-
cant differences in mean values were tested by analysis of
variance (ANOVA) and the Bonferroni’s post hoc test. The
differences were considered significant when P < 0.05.
Results
Effects of Dex preconditioning on kidney I/R
injury
Acute kidney I/R injury was associated with a 7.1-fold
increase in serum creatinine (S-creatinine) concentration
and a 7.0-fold increase in serum urea (S-urea) level as
compared to sham-operated controls. Histopathological
analysis of the kidneys harvested 24 h after I/R injury
showed marked loss of brush border, tubular dilatation,
cast formation, and cell lysis indicating severe ATN.
Dex preconditioning with higher 10 lg/kg bolus dose
decreased S-creatinine concentration 30% and S-urea
concentration 23% (Fig. 1A and B), while the smaller
dose (1 lg/kg) did not influence AKI-induced kidney
dysfunction. Interestingly, both Dex doses ameliorated
I/R-injury-induced ATN (Fig. 1C–F).
Continuous Dex infusions (0.1 or 0.3 lg/kg/min) did
not have any effect on serum creatinine or urea levels.
However, I/R-injury-induced ATN was ameliorated by the
infusion with 0.3 lg/kg/min (Fig. S1A–C).
In an additional study where we investigated the effects
of Dex and Nec-1 alone and in combination, Dex
decreased the serum creatinine level by 44% (P < 0.05)
and urea level by 22% in rats with I/R injury. Treatment
with necroptosis inhibitor Nec-1 alone, slightly but not
significantly, decreased serum creatinine level by 12% and
urea level by 6%. Cotreatment with Dex and Nec-1
decreased serum creatinine by 50% (P < 0.05) and urea
by 36%. There were no statistically significant differences
between Dex and Dex+ Nec-1 groups.
Effects of Dex postconditioning on kidney I/
R injury
Dex postconditioning (1 or 10 mg/kg i.v. bolus after
40 min ischemic period and prior reperfusion phase), did
not influence kidney function or the degree of ATN.
(Fig. 2A–C).
Effects of fadolmidine preconditioning
on kidney I/R injury
As compared to untreated RIR group, fadolmidine pre-
conditioning with 10 lg/kg bolus decreased S-creatinine
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and S-urea by and 19% and 17%, respectively, however,
the differences did not reach statistical significance. Smal-
ler (1 mg/kg) fadolmidine bolus did not have any effect
on S-creatinine or S-urea. Neither of the fadolmidine
doses affected the I/R-injury-induced ATN. (Fig. 2A–F).
Effects of fadolmidine postconditioning
on kidney I/R injury
Fadolmidine postconditioning (1 or 10 mg/kg) bolus
administered after 40 min of ischemia, did not have any
effect on S-creatinine, S-urea, or to the degree of tubular
necrosis. (Fig. S3A–C).
Hemodynamic effects of Dex
and fadolmidine
Mean arterial blood pressure (MAP) and heart rate (HR)
at baseline before administration of drugs averaged
107.1  11.3 mmHg and 405  35 bpm, respectively,
and did not differ between the treatment groups
(ANOVA P = 0.09 and 0.32, respectively).
Dex decreased blood pressure (BP) more prominently
than fadolmidine (Figs. 3 and 4). In bolus groups, the
percentage change in MAP was dose-dependent with both
drugs (Fig. 3A). Both Dex infusion rates (0.1 lg/kg/min




Figure 1. Effects of dexmedetomidine (Dex) preconditioning on serum creatinine and urea levels (A and B) and on kidney histology (C–F) in rats
with renal ischemia-reperfusion injury. Representative photomicrographs from sham-operated rats (C), untreated rats with I/R injury (D), and rats
with I/R injury treated with Dex 10 lg/kg bolus (E) are given. Magnification 1009, scale bar 200 lm. Quantification of kidney acute tubular
necrosis (ATN) score assessed by percentage of damaged tubules is given in (F). Sham denotes sham-operated rats; RIR, rats with renal I/R injury;
RIR + Dex1, rats with I/R injury treated with Dex 1 lg/kg bolus; RIR + Dex10, rats with I/R injury treated with Dex 10 lg/kg bolus. Means  SEM
are given, n = 5–11 in each group. *P < 0.05 vs. Sham; #P < 0.05 vs. RIR. ¤P < 0.05 vs. Dex 1 lg/kg bolus.
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compared to higher Dex bolus, whereas neither Fado
infusion influenced BP (Figs. 3B and 4B).
Percentage change in MAP 0–50 min after administra-
tion of drugs with Dex 10 lg/kg bolus differed from all
other bolus groups (Fig. 4A).
After a transient increase in BP, fadolmidine-treated
animals receiving lower dose showed a similar decrease
in the BP than the group receiving saline, while the
higher dose had a slight hypotensive effect (Fig. 4A).
The transient increase in BP occurred after 2 min with
bolus dosing and after four with infusions. The biggest
percentage change in MAP within bolus groups was
caused by Dex 10 lg/kg bolus 8 min after administra-
tion of drugs. Within infusions, the biggest decrease
occurred in Dex 0.3 lg/kg/min group after 18 min
(Fig. 3A and B).
Dex decreased also HRmore profoundly than fadolmidine.
Dex 0.1 lg/kg/min infusion decreased HR more than Dex
0.3 lg/kg/min infusion. With boluses and with Fado infu-
sions, decrease in HR was dose-dependent (Fig. 3C and D).
Plasma Dex concentration
Plasma Dex concentrations 15, 30, 120, and 180 min after
the 10 lg/kg bolus administration were 2.8, 0.80, 0.28,
and 0.16 ng/mL, respectively. Calculated from the mea-
sured time points, the plasma dex concentration at time




Figure 2. Effects of fadolmidine preconditioning on serum creatinine and urea levels (A and B) and on kidney histology (C–F) in rats with renal
ischemia-reperfusion injury. Representative photomicrographs from sham-operated rats (C), untreated rats with I/R injury (D), and rats with I/R
injury treated with fadolmidine 10 lg/kg bolus (E) are given. Magnification 1009, scale bar 200 lm. Quantification of kidney acute tubular
necrosis (ATN) score assessed by percentage of damaged tubules is given in (F). RIR + Fado1 denotes rats with I/R injury treated with fadolmidine
(Fado) 1 lg/kg bolus; RIR + Fado10, rats with I/R injury treated with Fado 10 lg/kg bolus. For other abbreviations, see Figure 1. Means  SEM
are given, n = 5–18 in each group. *P < 0.05 vs. Sham.
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ischemic period started) and time point 40 min (corre-
sponding time point when reperfusion was initiated) were
0.38 and 0.33 ng/ml, respectively.
Plasma Dex concentrations at time point 90 min after
continuous infusion with infusion rates 0.1 and 0.3 lg/
kg/min were 0.58 and 1.3 ng/mL, respectively.
(A) (B)
(C) (D)
Figure 3. Effects of dexmedetomidine and fadolmidine on hemodynamics during the experimental procedure in rats with renal ischemia-
reperfusion injury. Percentage change from baseline MAP is given in (A and B). Percentage change in HR is given in (C and D). Timescale on
x-axis begins when drugs were administrated. Ischemic period begins 60 min after administration of drugs and lasts for 40 min. Maximum
decreases in blood pressure and heart rate are given in (C and D). n = 5–6 in each group. MAP, mean arterial blood pressure; HR, heart rate. For
other abbreviations, see Figures 1 and 4.
(A) (B)
Figure 4. Effects of dexmedetomidine (Dex) and fadolmidine on MAP before ischemic period. Percentage change in MAP from baseline,
represented with AUC values, during 0–50 min time period after administration of drugs for bolus groups are given in (A) and for infusion groups
in (B). n = 5–6 in each group. *P < 0.05 vs. NaCl 0.9%; #P < 0.05 vs. Dex 1 lg/kg bolus; ¤P < 0.05 vs. Dex 10 lg/kg bolus; SP < 0.05 vs. Dex
0.1 lg/kg/min infusion; aP < 0.05 vs. Dex 0.3 lg/kg/min infusion. AUC, area under curve; MAP, mean arterial blood pressure; min, minutes, NaCl
0.9%, Sodium chloride 0.9%. For other abbreviations see Figures 1 and 4.
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Effects of Dex on renal inflammation,
autophagy, p38 and eNOS
Renal I/R injury was associated with a 2.6-fold increase in
the number of ED1-positive inflammatory cells in the kid-
ney as compared to sham-operated controls. The higher
dose of Dex suppressed the I/R-injury-induced monocyte/
macrophage infiltration in the renal parenchyma (Fig. 5).
Dex prevented the I/R-induced decrements in the total
(14 kDa/b-actin) and relative (14 kDa/16 kDa ratio)
expression levels of the active short form of autophagy
marker LC-3B (Fig. 6A and B).
The total expression of p38 MAPK was elevated to 1.6-
fold in I/R animals while expression of its phosphorylated
form was increased by 1.4-fold. Dex further increased the
expression of both the total and phosphorylated forms of
p38 MAPK (Fig. 6C and D).
I/R injury increased renal eNOS expression, both in the
presence and in the absence of Dex.
I/R injury did not have any effect on phosphorylated
eNOS expression, whereas Dex treatment increased it sig-
nificantly (Fig. 6E and F).
Dex-induced changes in renal
transcriptomics
Dex treatment altered the expression of 306 genes as
compared to untreated I/R group. 245 of these genes
were downregulated with Dex and 61 genes were upreg-
ulated. There were 17 enriched “Kyoto Encyclopedia of
Genes and Genomes” (KEGG) pathways among all regu-
lated genes, of which extracellular matrix (ECM)-recep-
tor interaction, hypertrophic cardiomyopathy,
(transforming growth factor) TGF-b signaling, dilated
cardiomyopathy, focal adhesion, regulation of actin cyto-
skeleton, chemokine signaling, and pathways in cancer
pathways were most significantly enriched (Table 2.).
Ingenuity analysis revealed inhibition of Rac and nuclear
factor (erythroid-derived 2)-like 2 pathways, whereas
“aryl hydrocarbon receptor” (AHR) pathway was acti-
vated. Dex decreased the expression of Rab27b, Rasa2
and CDC42-binding protein kinase alpha isoform B,
which are all associated to RAC signaling. Also expres-
sion of two RAB GTPases (also members of RAS super-
family) associated genes, Rabgap1 and Rabep1, decreased
with Dex treatment. Moreover, Ingenuity analysis
revealed also, that Dex treatment decreased the expres-
sion of inflammatory marker CD44 mRNA levels.
(Fig. 7).
Effects of Dex on TLR-4, Akt, SIRT1,
and AMPK expressions
Acute kidney I/R injury was associated with a 1.6-fold
increase in TLR-4 expression. Dex did not influence renal
TLR-4 expression. (Fig. 8A).
(A) (B)
(C) (D)
Figure 5. Effects of dexmedetomidine on monocyte/macrophage infiltration (ED1-immunopositive cells) (A–D) in rats with renal ischemia-
reperfusion injury. Representative photomicrographs from sham-operated rats (A) and untreated rats with I/R injury (B) and rats with I/R injury
treated with dexmedetomidine 10 lg/kg bolus (C) are given. Magnification 2009, scale bar 100 lm. Quantification of ED1-positive cells in the
kidney is given in (D). Means  SEM are given, n = 10–11 in each group. *P < 0.05 vs. Sham. #P < 0.05 vs. RIR. For abbreviations see Figure 1.
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The total Akt expression was increased by 2.5-fold and
the level of phosphorylated-Akt by 6.2-fold in I/R animals
as compared to sham group while Dex did not have any
significant effect on the Akt expressions (Fig. 8B–D).
The nuclear SIRT1 expression was increased by 26.2-
fold in I/R animals, whereas Dex treatment resulted to a
17.5-fold expression of SIRT1 compared to sham group
(Fig. S4A).
The I/R injury led to a 70% decrease in the ratio of
phosphorylated/total AMPK expression when compared
to sham-operated rats, albeit the total expression of
AMPK increased by 150%. Dex did not affect the phos-
phorylation level, nor the total expression of AMPK (Fig.
S4B–D).
Effects of Dex on serum biochemistry
Acute kidney I/R injury was associated with 84% and
340% increases in the serum concentrations of alanine
aminotransferase and aspartate aminotransferase, respec-
tively, as compared to sham-operated controls, indicating




Figure 6. Effects of dexmedetomidine on kidney LC-3B, p38 MAPK and eNOS expressions in rats with renal ischemia-reperfusion injury. The
expression of LC-3B 14 kDa/16 kDa -ratio, measured by Western blot (20 lg total protein of the whole cell lysate per lane), is given in (A). The
expression level of LC-3B 14 kDa is given in (B). (n = 10–11). The expression of phosphorylated p38, measured by Western blot (20 lg total
protein of the whole cell lysate per lane), is given in (C). The expression level of total p38 is given in (D). (n = 6–7). The expression of
phosphorylated eNOS, measured by Western blot (20 lg total protein of the whole cell lysate per lane), is given in (E). The expression level of
total eNOS is given in (F) (n = 6). Means  SEM are given. n = 6–11 in each group. *P < 0.05 vs. Sham. For abbreviations, see Figure 1.
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Serum levels of gamma-glutamyl transferase were also
markedly elevated reflecting injury to the proximal
tubules (Table 1). Pretreatment with Dex 10 lg/kg
decreased serum alanine aminotransferase, aspartate ami-
notransferase, and gamma-glutamyl transferase levels
(Table 1).
The I/R-induced alterations in the serum potassium,
chloride, and phosphate concentrations were prevented by
Dex (Table 1). Neither the I/R injury nor Dex influenced
serum sodium, calcium, albumin, or protein concentra-
tions. Nor did the serum glucose, cholesterol, or triglycer-
ide levels differ between the groups. (n = 6–11 per
group).
Discussion
This study demonstrated the renoprotective effects of Dex
preconditioning in a murine model of I/R injury. We also
demonstrated that peripheral a2-AR agonist fadolmidine
did not protect kidneys, thus suggesting that the protec-
tive effects of Dex are, to some extent, mediated via cen-
tral a2-ARs. Finally, we performed kidney transcriptomics
profiling combined with the “Ingenuity Pathways Analysis”
Figure 7. a2-adrenergic receptors regulate CD 44. Ingenuity analysis
shows that a2A-ARs regulate CD44 through p38 MAPK. Also other
a2-adrenergic receptor subtypes and related pathways are shown.
The networks were generated through the use of IPA (Ingenuity
Systems, www.ingenuity.com). ADRA2, a2-adrenergic receptor.
(A) (B)
(C) (D)
Figure 8. Effects of dexmedetomidine on kidney TLR-4 and Akt expressions in rats with renal ischemia-reperfusion injury. The expression of TLR-
4 and housekeeping protein beta-actin, measured by Western blot (20 lg nuclear protein fraction per lane), are given in (A). The phosphorylation
level of Akt measured as Akt-P/Akt ratio and expressions of total Akt, phosphorylated-Akt and housekeeping protein beta-actin are given in
(B–D). Means  SEM from three different runs are given, n = 5–7 in each group. *P < 0.05 vs. Sham. For abbreviations see Figure 1.
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to identify the pathways involved in the renoprotective
effects of Dex.
Dex attenuates myocardial infarcts and protects against
the ischemic brain, intestine, liver, and kidney injuries, as
well as I/R-induced AKI-related lung injuries in animal
models (Maier et al. 1993; Kuhmonen et al. 1997; Jolkko-
nen et al. 1999; Ma et al. 2004; Gu et al. 2011a,b; Ibacache
et al. 2012; Kilic et al. 2012; Tufek et al. 2013). In our
study, Dex preconditioning bolus and, to a lesser extent,
infusion protected against I/R-induced acute kidney injury
reflected as decrements in the S-creatinine and histopatho-
logical damage while postconditioning did not provide
any tissue protection. In a majority of studies where Dex
has been shown to protect against tissue damage, Dex has
been administered before or during the ischemic period
by a bolus, infusion, or the combination of both (Maier
et al. 1993; Kuhmonen et al. 1997; Jolkkonen et al. 1999;
Ma et al. 2004; Gu et al. 2011b; Ibacache et al. 2012; Tu-
fek et al. 2013). In contrast, data on the effects of Dex
postconditioning are scarce. In some of these studies, the
effects of Dex have been beneficial (Dahmani et al. 2010;
Gu et al. 2011b; Kilic et al. 2012). Gu et al. (2011b) com-
bined various in vivo and in vitro I/R models and were
able to demonstrate that the renoprotective effects of Dex
Table 1. Effects of dexmedetomidine treatment on serum biochemistry in rats with kidney I/R injury.
Variable Sham (n = 7–10) RIR (n = 8–11) RIR + Dex (n = 6–10) ANOVA P-value
s-ALAT (U/L) 46.2  3.0 85.2  5.0* 56.6  3.2# <0.0001
s-AFOS (U/L) 262  16.2 293  23.3 259  22.7 0.4576
s-ASAT (U/L) 129  7.2 571  44.4* 316.1  39.5*,# <0.0001
s-GGT (U/l) <1.0 29.3  3.6* 16.1  3.6*,# <0.0001
s-Protein(g/L) 52.7  1.0 53.1  1.2 54.4  1.1 0.5429
s-Albumin (g/L) 28.2  0.5 28.1  0.7 28.9  0.6 0.6143
s-K (mmol/L) 4.6  0.1 6.6  0.3* 5.0  0.1# <0.0001
s-Na (mmol/L) 138  1.3 136  2.3 139  1.1 0.5285
s-Cl (mmol/L) 97.3  0.9 89.0  1.8* 98.2  1.6# 0.0005
s-Calsium (mmol/L) 2.4  0.0 2.4  0.1 2.4  0.0 0.8251
s-Pi (mmol/L) 2.9  0.1 4.9  0.3* 3.6  0.3# <0.0001
s-Chol (mmol/L) 1.74  0.1 1.65  0.1 1.63  0.1 0.6517
s-Trigly (mmol/L) 0.82  0.1 0.85  0.1 0.63  0.1 0.1492
s-Gluk (mmol/L) 7.9  0.2 7.9  0.5 7.4  0.2 0.5623
Sham denotes sham-operated rats; RIR, rats with renal I/R injury; Dex, rats with I/R injury treated with dexmedetomidine at dose 10 lg/kg i.v.
Means  SEM are given, n = 6–11 in each group. *P < 0.05 vs. Sham; #P < 0.05 vs. RIR.
Table 2. The enriched KEGG pathways among all regulated genes.
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were linked to suppression of the HMBG1-TLR4 proin-
flammatory signaling pathway. In the same study, Dex
postconditioning protected against I/R-induced kidney
damage. However, while I/R injury increased kidney TLR4
expression in the present study, Dex did not seem to have
an effect on it, apparently depicting the differences in
experimental settings between the aforementioned studies.
a2-AR agonists act through binding to G-protein-
coupled a2-AR, of which there are three subtypes in
humans (a2A, a2B, and a2C). These receptors are found
ubiquitously in the central, peripheral, and autonomic
nervous systems, as well as in vital organs and blood
vessels. (Kaur and Singh 2011). Human and rat kidneys
contain all three types of a2-ARs (Cussac et al. 2002)
and rats have also a2D ARs, which is a rodent species
variant of human a2A-AR (Lehtimaki et al. 2008). Beside
a2-ARs, alpha1 adrenoceptors (a1-AR) are also widely
distributed and can be found in the kidneys with a ratio
of ~1:3 compared to a2-ARs (Schmitz et al. 1981).
Dex is highly selective a2-AR agonist (Hamasaki et al.
2002) and its sedative actions come mainly through
a2A-ARs of locus ceruleus of the brain stem and analgesic
actions through a2A-ARs in the spinal cord. In the heart,
a2-AR agonists induce bradycardia and in peripheral blood
vessels, a2-AR agonists cause sympatholysis-mediated
long-term vasodilatation while in the smooth muscle cells a
transient a2 and a1 receptor-mediated vasoconstriction
may be noted (Lehtimaki et al. 2008; Kaur and Singh
2011). Fadolmidine is another a2-AR agonist having antin-
ociceptive effects when administrated intrathecally (Lehti-
maki et al. 2008). It is a full agonist at all three subtypes
of human a2-ARs (a2A, a2B, and a2C) and activates
also rodent a2D-ARs, as well as human a1A- and a1B-ARs.
(Lehtimaki et al. 2008; Leino et al. 2009).
In the current study, Dex provided protection against
the I/R-induced renal dysfunction and histopathological
damage while fadolmidine did not. Both substances low-
ered BP slightly when the preconditioning bolus was
given but significant drop was only reached with a con-
tinuous Dex infusion. In contrast to Dex, Fado is also a
full agonist at the a1-ARs, thus explaining the observed
transient rise in BP following the bolus (Lehtimaki et al.
2008). The BP-dependent effects seemed to play a minor
role in this study as the Dex infusion causing the most
pronounced hypotensive effect did not affect the serum
creatinine levels. However, the involvement of ischemic
preconditioning (IPC) in this study cannot be completely
ruled out (Sharfuddin and Molitoris 2011).
The aim of the present study was also to investigate
whether the renoprotective effects of Dex were mediated
via central and/or peripheral a2-ARs. Dex exerts potent
sympatholytic and analgetic properties through central
and peripheral a2-ARs, while fadolmidine, due to its
polarity and less lipidofilic properties, acts mainly periph-
erally (Lehtimaki et al. 2008; Leino et al. 2009). Renal
SNS plays an important role in the development of ische-
mic acute renal failure and nociceptive signaling is known
to activate SNS (Fujii et al. 2003). Dex reduces renal sym-
pathetic nerve activity and catecholamine release by cen-
tral sympatho-inhibitory effect. It also decreases the
release of lactate from the tissues and thus relieves the
recovery from ischemic events (Xu et al. 1998; Taoda
et al. 2001; Willigers et al. 2003).
Along with the previous studies suggesting that Dex
might protect against kidney I/R injury through it anti-
inflammatory properties (Gu et al. 2011b), we noted a
marked protective effect of Dex against the I/R-induced
infiltration of monocyte/macrophage cells (ED1).
Autophagy is a cell protecting mechanism which is
activated in response to stress signals from endoplasmic
reticulum (Ogata et al. 2006). In the current study, auto-
phagy measured as the presence of autophagy marker
Light Chain 3 (LC-3B), was markedly downregulated by
I/R. This, while revealing a disturbance in cellular survival
signaling in this model, also proposes a novel organopro-
tective mechanism for Dex, as Dex prevented the impair-
ment of autophagic response hence maintaining the
crucial degradation and recycling of various cellular com-
ponents. This finding also incites further studies revealing
the more detailed mechanisms of Dex in affecting the
individual steps of autophagic flux, that is, the total auto-
phagic process starting with the sequestration of p62 and
autophagosome synthesis and ending to the degradation
of cellular materials in autolysosomes.
a2-receptors activate mitogen activated protein kinases
(MAPK) and activation of p38 MAPK is known to pro-
tect against I/R injury in the rat heart and to contribute
to the commencement of autophagic response (Mocanu
et al. 2000; Nakano et al. 2000; Bonventre 2002; Cussac
et al. 2002; Tang et al. 2008). In our study, the I/R
induced the total level of renal p38 expression. However,
the phosphorylated, active form, of p38 was upregulated
only with Dex indicating enhancements in the activities
of prosurvival kinase pathways. In addition, the active
form of eNOS, a downstream mediator of p38, was signif-
icantly induced by Dex.
As to further investigate the cytoprotective mechanisms
of Dex in this model, we studied the effect of a death recep-
tor-interacting protein kinase 1 (RIPK1) inhibitor, Nec-1.
Necroptosis, a form of programmed necrosis, involves a
tumor necrosis factor (TNF)-induced cell death pathway
participating in the experimental models of brain, cardiac,
and renal ischemia-reperfusion injury (Linkermann et al.
2012). In line with the previous studies, we also noticed
minor but nonsignificant renoprotective effects by Nec-1 as
reflected by decrements in S-creatinine and S-urea levels.
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The renoprotective effects of Dex, when given as monother-
apy, clearly exceeded those achieved with Nec-1. A minor
additive protective effect was found when Dex and Nec-1
were given as combination, thus suggesting that the preven-
tion of necroptosis was not a major cell-protective mecha-
nism of Dex.
Dex treatment altered the expression of 306 genes
of which 245 were downregulated and 61 upregulated.
These genes represented 17 enriched KEGG pathways. Dex
downregulated TGFb-pathway which is a known proin-
flammatory mediator in renal injury (Spurgeon et al.
2005). Dex also suppressed “Hypertrophic Cardiomyopa-
thy”-pathway (broadly overlapping the “Dilated Cardiomy-
opathy”-pathway) which promotes inflammatory signaling,
apoptosis, cellular senescence, activation of the renin–
angiotensin system (RAS) and induction of the insulin-like
growth factor 1 (IGF-1). Interestingly, the inhibition of
RAS is a key therapeutic approach to prevent the develop-
ment of renal damage among hypertensives and diabetics.
In addition, Dex has been shown to suppress the (RAS
inducible) janus kinase/signal transducer and activator of
transcription pathway in a murine model of renal I/R (Si
et al. 2013). Reduced IGF-1 signaling, in turn, is suggested
to contribute to the “antiaging” effects achieved with calo-
ric restriction (Barzilai and Bartke 2009).
Dex downregulated the expression of “ECM-receptor
interaction”-pathway in which the CD44 gene is included.
The CD44 receptor has a crucial role in cell adhesion and
promotes the transendothelial migration of leukocytes to
injured tissue (Chase et al. 2012). Therefore, Dex-induced
decrease in CD44 expression is likely to contribute to the
decreased leukocyte extravasation after I/R injury. While
several proinflammatory pathways were inhibited by Dex,
there was a concomitant activation of the organoprotec-
tive AHR pathway. AHR pathway consists of a family of
transcriptional regulators which are activated in response
to hypoxia and are capable of inhibiting the proinflam-
matory mediator NF-кB.
In conclusion, Dex preconditioning, but not Dex post-
conditioning or treatment with a peripheral a2-AR agonist
fadolmidine, ameliorates kidney I/R injury and inflamma-
tory response. The renoprotective effects of Dex were medi-
ated, at least in part, through central mechanisms and
associated with increased renal p38 MAPK, maintenance of
autophagy and suppression of several pathways promoting
hypertrophy and inflammatory signaling.
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Figure S1. Effects of dexmedetomidine infusions on
serum creatinine and urea levels (A and B) and on kidney
histology (C) in rats with renal ischemia-reperfusion (I/
R) injury. Quantification of kidney acute tubular necrosis
(ATN) score assessed by percentage of damaged tubules is
given in (C). RIR + Dex0.1 denotes rats with I/R injury
treated with Dex 0.1 lg/kg/min infusion; RIR + Dex0.3,
rats with I/R injury treated with Dex 0.3lg/kg/min
infusion. For other abbreviations see Figure 1.
Means  SEM are given, n = 5–11 in each group.
*P < 0.05 vs. Sham; #P < 0.05 vs. RIR.
Figure S2. Effects of dexmedetomidine postconditioning
on serum creatinine and urea levels (A and B) and on
kidney histology (C) in rats with renal ischemia-reperfu-
sion (I/R) injury. Quantification of kidney acute tubular
necrosis (ATN) score assessed by percentage of damaged
tubules is given in (C). RIR + Dex1 denotes rats with I/R
injury treated with Dex 1 lg/kg postconditioning bolus;
RIR + Dex10, rats with I/R injury treated with Dex
10 lg/kg postconditioning bolus. For other abbreviations
see Figure 1. Means  SEM are given, n = 5–11 in each
group. *P < 0.05 vs. Sham.
Figure S3. Effects of fadolmidine postconditioning on
serum creatinine and urea levels (A and B) and on kidney
histology (C) in rats with renal ischemia-reperfusion
injury. Quantification of kidney acute tubular necrosis
(ATN) score assessed by percentage of damaged tubules is
given in (C). RIR + Fado1 denotes rats with I/R injury
treated with fadolmidine (Fado) 1 lg/kg postconditioning
bolus; RIR + Fado10, rats with I/R injury treated with
Fado 10 lg/kg postconditioning bolus. For other abbrevi-
ations see Figure 1. Means  SEM are given, n = 5–18 in
each group. *P < 0.05 vs. Sham.
Figure S4. Effects of dexmedetomidine on kidney SIRT1
and AMPK expressions in rats with renal ischemia-reper-
fusion (I/R) injury. The expression of SIRT1 and house-
keeping protein beta-actin, measured by Western blot
(20 lg nuclear protein fraction per lane), are given in
(A). The phosphorylation level of AMPK measured as
AMPK-P/AMPK ratio and expressions of total AMPK,
phosphorylated-AMPK and housekeeping protein beta-
actin are given in (B–D). Means  SEM from three dif-
ferent runs are given, n = 5–7 in each group. *P < 0.05
vs. Sham. For abbreviations see Figure 1.
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